当前位置: X-MOL 学术Eur. J. Nucl. Med. Mol. Imaging › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Lymphoscintigraphy and sentinel lymph node biopsy in vulvar carcinoma: update from a European expert panel.
European Journal of Nuclear Medicine and Molecular Imaging ( IF 8.6 ) Pub Date : 2020-01-02 , DOI: 10.1007/s00259-019-04650-8
Angela Collarino 1 , Valentina Fuoco 2 , Giorgia Garganese 3, 4 , Lenka M Pereira Arias-Bouda 5, 6 , Germano Perotti 1 , Gianpiero Manca 7 , Sergi Vidal-Sicart 8 , Francesco Giammarile 9 , Lioe-Fee de Geus-Oei 5, 10 , Giovanni Scambia 3, 11 , Alessandro Giordano 1, 2 , Renato A Valdés-Olmos 5, 12, 13 , Marco Maccauro 14
Affiliation  

PURPOSE This study aimed to update the clinical practice applications and technical procedures of sentinel lymph node (SLN) biopsy in vulvar cancer from European experts. METHODS A systematic data search using PubMed/MEDLINE database was performed up to May 29, 2019. Only original studies focused on SLN biopsy in vulvar cancer, published in the English language and with a minimum of nine patients were selected. RESULTS Among 280 citations, 65 studies fulfilled the inclusion criteria. On the basis of the published evidences and consensus of European experts, this study provides an updated overview on clinical applications and technical procedures of SLN biopsy in vulvar cancer. CONCLUSIONS SLN biopsy is nowadays the standard treatment for well-selected women with clinically negative lymph nodes. Negative SLN is associated with a low groin recurrence rate and a good 5-year disease-specific survival rate. SLN biopsy is the most cost-effective approach than lymphadenectomy in early-stage vulvar cancer. However, future trials should focus on the safe extension of the indication of SLN biopsy in vulvar cancer. Although radiotracers and optical agents are widely used in the clinical routine, there is an increasing interest for hybrid tracers like indocyanine-99mTc-nanocolloid. Finally, it is essential to standardise the acquisition protocol including SPECT/CT images, and due to the low incidence of this type of malignancy to centralise this procedure in experienced centres for personalised approach.

中文翻译:

外阴癌的淋巴显像和前哨淋巴结活检:来自欧洲专家小组的最新信息。

目的本研究旨在更新欧洲专家对外阴癌的前哨淋巴结(SLN)活检的临床实践应用和技术程序。方法截至2019年5月29日,使用PubMed / MEDLINE数据库进行了系统的数据检索。仅以英语发表的原始研究侧重于外阴癌的SLN活检,并选择了至少9名患者。结果在280次引用中,有65项研究符合纳入标准。根据已发表的证据和欧洲专家的共识,本研究提供了有关外阴癌中SLN活检的临床应用和技术程序的最新概述。结论如今,SLN活检已成为临床淋巴结阴性的精选女性的标准治疗方法。阴性SLN与低腹股沟复发率和良好的5年疾病特异性生存率相关。在早期外阴癌中,SLN活检是比淋巴结清扫术最具成本效益的方法。但是,未来的试验应侧重于外阴癌中SLN活检指征的安全性扩展。尽管放射性示踪剂和光学试剂广泛用于临床常规中,但对混合示踪剂(如吲哚菁-99mTc-纳米胶体)的兴趣日益增加。最后,必须标准化包括SPECT / CT图像在内的采集协议,并且由于这种类型的恶性肿瘤的发生率较低,因此必须将该程序集中在经验丰富的中心进行个性化处理。在早期外阴癌中,SLN活检是比淋巴结清扫术最具成本效益的方法。但是,未来的试验应侧重于外阴癌中SLN活检指征的安全性扩展。尽管放射性示踪剂和光学试剂广泛用于临床常规中,但对混合示踪剂(如吲哚菁-99mTc-纳米胶体)的兴趣日益增加。最后,必须标准化包括SPECT / CT图像在内的采集协议,并且由于这种类型的恶性肿瘤的发生率较低,因此必须将该程序集中在经验丰富的中心进行个性化处理。在早期外阴癌中,SLN活检是比淋巴结清扫术最具成本效益的方法。但是,未来的试验应侧重于外阴癌中SLN活检指征的安全性扩展。尽管放射性示踪剂和光学试剂广泛用于临床常规中,但对混合示踪剂(如吲哚菁-99mTc-纳米胶体)的兴趣日益增加。最后,必须标准化包括SPECT / CT图像在内的采集协议,并且由于这种类型的恶性肿瘤的发生率较低,因此必须将该程序集中在经验丰富的中心进行个性化处理。对混合示踪剂如吲哚菁-99mTc-纳米胶体的兴趣日益增加。最后,必须标准化包括SPECT / CT图像在内的采集协议,并且由于这种类型的恶性肿瘤的发生率较低,因此必须将该程序集中在经验丰富的中心进行个性化处理。对混合示踪剂如吲哚菁-99mTc-纳米胶体的兴趣日益增加。最后,必须标准化包括SPECT / CT图像在内的采集协议,并且由于这种类型的恶性肿瘤的发生率较低,因此必须将该程序集中在经验丰富的中心进行个性化处理。
更新日期:2020-01-02
down
wechat
bug